BRPI1015053A2 - partículas similares a vírus da influenza quiméricas compreendendo hemaglutinina - Google Patents

partículas similares a vírus da influenza quiméricas compreendendo hemaglutinina

Info

Publication number
BRPI1015053A2
BRPI1015053A2 BRPI1015053A BRPI1015053A BRPI1015053A2 BR PI1015053 A2 BRPI1015053 A2 BR PI1015053A2 BR PI1015053 A BRPI1015053 A BR PI1015053A BR PI1015053 A BRPI1015053 A BR PI1015053A BR PI1015053 A2 BRPI1015053 A2 BR PI1015053A2
Authority
BR
Brazil
Prior art keywords
chimeric influenza
plant
particles
influenza virus
hemagglutinin
Prior art date
Application number
BRPI1015053A
Other languages
English (en)
Inventor
Vezina Louis-Philippe
Couture Manon
D'aoust Marc-Andre
Dargis Michele
Lavoie Pierre-Olivier
Original Assignee
Medicago Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicago Inc filed Critical Medicago Inc
Publication of BRPI1015053A2 publication Critical patent/BRPI1015053A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16223—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"partículas similares a vírus da influenza quiméricas compreendendo hemaglutinina". a presente invenção refere-se a um método para sintetização de partículas similares a vírus da influenza quiméricas (vlps) dentro de uma planta ou uma porção de uma planta. o método envolve expressão de ha de influenza quimérica em uma planta ou uma porção de uma planta. a invenção é também direcionada a uma vlp compreendendo proteína de ha de influenza quimérica e lipídeos de plantas. a invenção é também direcionada a um ácido nucleico que codifica ha de influenza quimérica, bem como vetores. as vlps podem ser usadas para formular vacinas da influenza, ou podem ser usadas para enriquecer as vacinas existentes.
BRPI1015053A 2009-06-24 2010-06-25 partículas similares a vírus da influenza quiméricas compreendendo hemaglutinina BRPI1015053A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22016109P 2009-06-24 2009-06-24
PCT/CA2010/000983 WO2010148511A1 (en) 2009-06-24 2010-06-25 Chimeric influenza virus-like particles comprising hemagglutinin

Publications (1)

Publication Number Publication Date
BRPI1015053A2 true BRPI1015053A2 (pt) 2019-07-09

Family

ID=43385835

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1015053A BRPI1015053A2 (pt) 2009-06-24 2010-06-25 partículas similares a vírus da influenza quiméricas compreendendo hemaglutinina

Country Status (25)

Country Link
US (1) US10272148B2 (pt)
EP (2) EP3228627A1 (pt)
JP (2) JP5871796B2 (pt)
KR (1) KR101377725B1 (pt)
CN (1) CN102482328B (pt)
AU (1) AU2010265766B2 (pt)
BR (1) BRPI1015053A2 (pt)
CA (1) CA2762042C (pt)
DK (1) DK2445928T3 (pt)
ES (1) ES2669303T3 (pt)
HK (1) HK1245294A1 (pt)
HR (1) HRP20180706T1 (pt)
HU (1) HUE039100T2 (pt)
IL (1) IL216937A (pt)
IN (1) IN2012DN00650A (pt)
MX (2) MX349924B (pt)
MY (1) MY182643A (pt)
NO (1) NO2445928T3 (pt)
NZ (1) NZ597401A (pt)
PL (1) PL2445928T3 (pt)
PT (1) PT2445928T (pt)
SG (1) SG176820A1 (pt)
SI (1) SI2445928T1 (pt)
WO (1) WO2010148511A1 (pt)
ZA (1) ZA201200481B (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2615372A1 (en) * 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
WO2009076778A1 (en) 2007-11-27 2009-06-25 Medicago Inc. Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
WO2010003235A1 (en) * 2008-07-08 2010-01-14 Medicago Inc. Soluble recombinant influenza antigens
CA2787099A1 (en) 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
JP5941841B2 (ja) 2009-05-26 2016-06-29 アイカーン スクール オブ メディシン アット マウント サイナイ 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用
BRPI1015053A2 (pt) 2009-06-24 2019-07-09 Medicago Inc partículas similares a vírus da influenza quiméricas compreendendo hemaglutinina
SI3354657T1 (sl) 2009-09-22 2022-05-31 Medicago Inc. Postopek za pripravo iz rastlin izpeljanih beljakovin
US9701723B2 (en) 2010-02-18 2017-07-11 Icahn School Of Medicine At Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
WO2011123495A1 (en) 2010-03-30 2011-10-06 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
TWI526539B (zh) 2010-12-22 2016-03-21 苜蓿股份有限公司 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp
TWI670373B (zh) * 2011-02-08 2019-09-01 淡馬錫生命科學實驗室有限公司 用於有效率地表面呈示抗原蛋白質之新穎表現匣
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
HUE044089T2 (hu) 2011-07-18 2019-09-30 Inst Res Biomedicine Neutralizáló anti-influenza A antitestek és alkalmazásaik
EP2758075B1 (en) * 2011-09-20 2023-05-03 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
RU2682752C2 (ru) 2011-09-30 2019-03-21 Медикаго Инк. Повышение выхода вирусоподобных частиц в растениях
US11390878B2 (en) 2011-09-30 2022-07-19 Medicago Inc. Increasing protein yield in plants
IN2015DN03070A (pt) 2012-11-27 2015-10-02 Univ Pittsburgh
EP2934581B1 (en) * 2012-12-18 2022-09-14 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
KR102199018B1 (ko) 2013-03-28 2021-01-07 메디카고 인코포레이티드 식물에서 인플루엔자 바이러스-유사 입자 생산
US12467058B2 (en) 2013-03-28 2025-11-11 Aramis Biotechnologies Inc. Influenza virus-like particle production in plants
CN105722976A (zh) * 2013-06-06 2016-06-29 诺华股份有限公司 流感病毒重配
WO2015103704A1 (en) * 2014-01-10 2015-07-16 Medicago Inc. Cpmv enhancer elements
US10563213B2 (en) 2014-03-27 2020-02-18 Medicago Inc. Modified CPMV enhancer elements
CN105233302B (zh) * 2014-07-10 2018-10-19 中国人民解放军军事医学科学院生物工程研究所 一种流感血凝素糖蛋白多聚物纳米颗粒的制备方法
JP2018504412A (ja) * 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
RU2728472C2 (ru) 2015-07-02 2020-07-29 Медикаго Инк. Активатор сигнального пути жасмоновой кислоты
KR101755114B1 (ko) * 2015-09-08 2017-07-06 건국대학교 산학협력단 여러 클레이드의 고병원성 조류인플루엔자 h5 바이러스에 대한 넓은 항체 반응을 유도하는 키메릭 바이러스 유사입자 백신
US20180326040A1 (en) * 2015-11-16 2018-11-15 Kansas State University Research Foundation Influenza virus vaccine and vaccine platform
SG10202108573TA (en) * 2016-02-03 2021-09-29 Cg Discovery Inc Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites
EP3471767A4 (en) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
JP6622825B2 (ja) * 2018-01-25 2019-12-18 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ Ａ型インフルエンザウイルス中和抗体及びその使用法
MX2020009495A (es) 2018-03-14 2020-12-07 Medicago Inc Potenciador de la expresion en plantas.
WO2019246363A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
JP2021528970A (ja) 2018-06-27 2021-10-28 メディカゴ インコーポレイテッド インフルエンザウイルスヘマグルチニン変異体
WO2020181354A1 (en) 2019-03-14 2020-09-17 Mitsubishi Tanabe Pharma Corporation Endogenous plant expression enhancer
CA3131096A1 (en) 2019-04-05 2020-10-08 Chi-Huey Wong Sialidase-resistant saccharide and method of making and using the same
WO2020219719A1 (en) 2019-04-24 2020-10-29 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
EP4031558A4 (en) * 2019-09-20 2023-05-31 Academia Sinica CHIMERIC HEMAGGLUTININ PROTEIN AND VACCINE COMPOSITION CONTAINING IT
CN115003328A (zh) 2019-10-22 2022-09-02 西奈山伊坎医学院 重组神经氨酸酶及其用途
JP2020048568A (ja) * 2019-11-22 2020-04-02 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ Ａ型インフルエンザウイルス中和抗体及びその使用法
CA3182526A1 (en) 2020-05-08 2021-11-11 Academia Sinica Chimeric influenza vaccines
WO2022221837A2 (en) 2021-04-12 2022-10-20 Academia Sinica Improved coronavirus vaccine
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
CA3268566A1 (en) 2023-04-08 2024-10-17 Rock Biomedical Inc. METHODS AND COMPOSITIONS FOR TARGETED DISTRIBUTION BY POLYMERSOMES
NZ825394A (en) 2023-04-08 2026-03-27 Rock Biomedical Inc Methods and compositions for dendritic cell targeting nano-delivery
CN121175414A (zh) 2023-05-17 2025-12-19 磐石医药生技股份有限公司 Mgat1缺乏细胞及其用途

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428147A (en) 1983-04-15 1995-06-27 Mycogen Plant Science, Inc. Octopine T-DNA promoters
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
WO1986003224A1 (en) 1984-11-29 1986-06-05 Scripps Clinic And Research Foundation Polypeptides and antibodies related to deglycosylated viral glycoproteins
US4962028A (en) 1986-07-09 1990-10-09 Dna Plant Technology Corporation Plant promotors
US5232833A (en) 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
US6403865B1 (en) 1990-08-24 2002-06-11 Syngenta Investment Corp. Method of producing transgenic maize using direct transformation of commercially important genotypes
DE69213804T2 (de) 1991-03-28 1997-03-27 Rooperol Na Nv Zusammensetzungen von Phytosterolen mit Phytosterolinen als Immunmodulatoren
UA48104C2 (uk) 1991-10-04 2002-08-15 Новартіс Аг Фрагмент днк, який містить послідовність,що кодує інсектицидний протеїн, оптимізовану для кукурудзи,фрагмент днк, який забезпечує направлену бажану для серцевини стебла експресію зв'язаного з нею структурного гена в рослині, фрагмент днк, який забезпечує специфічну для пилку експресію зв`язаного з нею структурного гена в рослині, рекомбінантна молекула днк, спосіб одержання оптимізованої для кукурудзи кодуючої послідовності інсектицидного протеїну, спосіб захисту рослин кукурудзи щонайменше від однієї комахи-шкідника
US6326470B1 (en) 1997-04-15 2001-12-04 The Penn State Research Foundation Enhancement of accessibility of cellulose by expansins
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
GB9414118D0 (en) 1994-07-13 1994-08-31 Axis Genetics Ltd Modified plant viruses as vectors of heterologous peptides
WO1997004122A1 (en) 1995-07-20 1997-02-06 Washington State University Research Foundation Production of secreted foreign polypeptides in plant cell culture
US6042832A (en) 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
US20010006950A1 (en) 1998-02-11 2001-07-05 Juha Punnonen Genetic vaccine vector engineering
US6489537B1 (en) 1998-08-07 2002-12-03 The Trustees Of The University Of Pennsylvania Phytochelatin synthases and uses therefor
NZ510358A (en) 1998-08-11 2002-09-27 Large Scale Biology Corp Method for recovering proteins from the interstitial fluid of plant tissues
US6392121B1 (en) 1998-10-07 2002-05-21 Boyce Thompson Institute For Plant Research Gemini virus vectors for gene expression in plants
US6287570B1 (en) 1998-11-23 2001-09-11 Patricia L. Foley Vaccine against swine influenza virus
FR2791358B1 (fr) 1999-03-22 2003-05-16 Meristem Therapeutics Promoteurs chimeriques d'expression, cassettes d'expression, plasmides, vecteurs, plantes et semences transgeniques les contenant et leurs methodes d'obtention
MXPA01010921A (es) * 1999-04-29 2003-06-24 Syngenta Ltd Plantas resistentes a herbicidas.
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US7449188B2 (en) 2001-01-18 2008-11-11 Vlaams Interuniversitair Instituut Voor Biotechnologie Recombinant oligometric protein complexes with enhanced immunogenic potential
CN1997734A (zh) * 2002-02-13 2007-07-11 威斯康星旧生研究基金会 包装流感病毒载体的信号
EP3009507B1 (en) 2002-02-13 2020-06-24 Wisconsin Alumini Research Foundation Signal for packaging of influenza virus vectors
WO2003068804A2 (en) 2002-02-14 2003-08-21 Novavax, Inc. Novel insect cell line
CA2478294C (en) 2002-03-19 2013-09-03 Plant Research International B.V. Gntiii (udp-n-acetylglucosamine:beta-d mannoside beta (1,4)-n-acetylglucosaminyltransferase iii) expression in plants
ES2224792B1 (es) 2002-06-28 2007-02-16 Era Plantech, S.L. Produccion de peptidos y proteinas por acumulacion de cuerpos proteicos derivados de reticulos endoplasmico en plantas.
KR20060029214A (ko) 2003-05-05 2006-04-05 다우 아그로사이언시즈 엘엘씨 이식 유전자 식물 세포들로부터 유래된 안정한 면역예방적및 치료적 조성물들 및 생산방법
KR20060035596A (ko) * 2003-05-05 2006-04-26 보이스 톰슨 인스터튜트 포 플랜트 리서치 외래유전자도입 식물로부터 유래된 면역보호성 조성물을제조하기 위한 벡터와 세포
EP1633312A4 (en) 2003-06-16 2012-09-26 Medimmune Llc INFLUENZA HEMAGGLUTININE AND NEURAMINIDASE VARIANTS
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US7226781B1 (en) 2003-07-24 2007-06-05 Belyaev Alexander S Chaperone expression genomes
CN101166827B (zh) 2005-04-29 2013-09-04 开普敦大学 在植物中表达蛋白质
JP2009502789A (ja) 2005-07-19 2009-01-29 ダウ グローバル テクノロジーズ インコーポレイティド 組み換えインフルエンザワクチン
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
US20070042002A1 (en) 2005-08-16 2007-02-22 Hawaii Biotech, Inc. Influenza recombinant subunit vaccine
PT1937301E (pt) 2005-10-18 2015-09-14 Novavax Inc Partículas idênticas a vírus (vlps) da gripe funcionais
US8124103B2 (en) 2006-02-13 2012-02-28 Fraunhofer Usa, Inc Influenza antigens, vaccine compositions, and related methods
JP2009535306A (ja) 2006-04-21 2009-10-01 ダウ・アグロサイエンス・エル・エル・シー 鳥インフルエンザに対するワクチンおよび使用方法
WO2007130327A2 (en) 2006-05-01 2007-11-15 Technovax, Inc. Influenza virus-like particle (vlp) compositions
EP2023952B1 (en) 2006-05-18 2015-07-15 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
US8519113B2 (en) 2006-05-22 2013-08-27 Plant Bioscience Limited Bipartite system, method and composition for the constitutive and inducible expression of high levels of foreign proteins in plants
US20070286873A1 (en) 2006-05-23 2007-12-13 Williams John V Recombinant Influenza H5 Hemagluttinin Protein And Nucleic Acid Coding Therefor
EP2035565A4 (en) 2006-06-30 2010-07-21 Novavax Inc METHODS OF ENHANCING THE INCORPORATION OF PROTEINS IN VIRUS-LIKE PARTICLES (VLPs)
WO2008061243A2 (en) 2006-11-16 2008-05-22 Novavax, Inc. Respiratory syncytial virus-virus like particle (vlps)
US7730950B2 (en) 2007-01-19 2010-06-08 Halliburton Energy Services, Inc. Methods for treating intervals of a subterranean formation having variable permeability
US8697088B2 (en) 2007-05-25 2014-04-15 Novavax, Inc. VLPs derived from cells that do not express a viral matrix or core protein
PL2155880T3 (pl) 2007-06-15 2017-06-30 Medicago Inc. Modyfikacja wytwarzania glikoproteiny w roślinach
KR100964462B1 (ko) 2007-07-10 2010-06-16 성균관대학교산학협력단 형질전환 식물 유래의 조류독감 바이러스 백신 및 그 제조방법
WO2009076778A1 (en) 2007-11-27 2009-06-25 Medicago Inc. Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
CA2696764A1 (en) 2007-08-20 2009-02-26 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
GB0800272D0 (en) 2008-01-08 2008-02-13 Plant Bioscience Ltd Protein expression systems
EA034733B1 (ru) 2008-01-21 2020-03-13 Медикаго Инк. Нуклеиновая кислота для увеличенной экспрессии гемагглютинина вируса гриппа в растении и ее применение
WO2010003235A1 (en) 2008-07-08 2010-01-14 Medicago Inc. Soluble recombinant influenza antigens
DK2318530T3 (en) 2008-07-18 2016-10-03 Medicago Inc Ny epitope to immunization against influenza
WO2010025285A1 (en) 2008-08-27 2010-03-04 Arizona Board Of Regents For And On Behalf Of Arizona State University A dna replicon system for high-level rapid production of vaccines and monoclonal antibody therapeutics in plants
WO2010042551A2 (en) 2008-10-06 2010-04-15 Genvault Corporation Methods for providing cellular lysates from cell wall-containing samples
WO2010077712A1 (en) 2008-12-09 2010-07-08 Novavax, Inc. Bovine respiratory syncytial virus virus-like particle (vlps)
BRPI1015053A2 (pt) 2009-06-24 2019-07-09 Medicago Inc partículas similares a vírus da influenza quiméricas compreendendo hemaglutinina
SI3354657T1 (sl) 2009-09-22 2022-05-31 Medicago Inc. Postopek za pripravo iz rastlin izpeljanih beljakovin

Also Published As

Publication number Publication date
RU2569195C2 (ru) 2015-11-20
EP3228627A1 (en) 2017-10-11
CN102482328B (zh) 2014-11-26
MX2011013517A (es) 2012-05-23
SI2445928T1 (en) 2018-05-31
AU2010265766B2 (en) 2015-03-19
EP2445928A1 (en) 2012-05-02
EP2445928A4 (en) 2013-11-06
AU2010265766A1 (en) 2012-02-02
PT2445928T (pt) 2018-06-07
EP2445928B1 (en) 2018-03-28
JP6141228B2 (ja) 2017-06-07
MY182643A (en) 2021-01-27
HK1245294A1 (en) 2018-08-24
MX349924B (es) 2017-08-21
CA2762042C (en) 2012-11-20
ES2669303T3 (es) 2018-05-24
NO2445928T3 (pt) 2018-08-25
RU2012101946A (ru) 2013-07-27
ZA201200481B (en) 2013-05-29
US10272148B2 (en) 2019-04-30
CN102482328A (zh) 2012-05-30
PL2445928T3 (pl) 2018-07-31
JP2012530499A (ja) 2012-12-06
US20120189658A1 (en) 2012-07-26
WO2010148511A8 (en) 2011-03-10
NZ597401A (en) 2013-09-27
CA2762042A1 (en) 2010-12-29
DK2445928T3 (en) 2018-05-28
HK1170250A1 (en) 2013-02-22
KR101377725B1 (ko) 2014-03-27
HUE039100T2 (hu) 2018-12-28
JP5871796B2 (ja) 2016-03-01
MX392585B (es) 2025-03-19
IN2012DN00650A (pt) 2015-06-12
HRP20180706T1 (hr) 2018-06-01
WO2010148511A1 (en) 2010-12-29
IL216937A (en) 2017-01-31
SG176820A1 (en) 2012-01-30
JP2014158483A (ja) 2014-09-04
IL216937A0 (en) 2012-02-29
KR20120133371A (ko) 2012-12-10

Similar Documents

Publication Publication Date Title
MX392585B (es) Particulas similares al virus de la influenza quimericas que comprenden hemaglutinina.
TN2009000557A1 (en) Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant
MX370690B (es) Epitopo de inmunizacion de nuevo virus de la influenza.
WO2010003225A8 (en) Influenza virus-like particles (vlps) comprising hemagglutinin
WO2009076778A8 (en) Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
BR112013011194A2 (pt) partículas de glicoproteína semelhantes a vírus (vlps) da raiva.
BR112012033767A2 (pt) processo para produzir um vírus de interesse, para remover um agente adventício, e para remover um agente adventício, vírus,e, composição imunogênica ou vacina.
BR112013032723A2 (pt) antígenos amplamente reativos computacionalmente otimizados para influenza h1n1
MX2018007860A (es) Vacunas recombinantes contra el zika.
BRPI0906509A2 (pt) constructo de expressão de gene, sistema de expressão de gene, varaiação de um sistema de expressão de gene, processo para aumentar a expressão ou melhorar a atividade translacional de uma sequência derivada de um segmento do genoma de rna-2 de um vírus bipartido, métodos para expressar uma proteína de interesse em um organismo hospedeiro, para melhorar a tradução de uma proteína de interesse heteróloga de um gene ou quadro de leitura aberto, para expressar uma proteína constructo de expressão de gene , sistema de expressão de gene, variação de um sistema de expressão de gene, processo para aumentar a expressão ou melhorar a atividade translacional de uma sequência derivada de um segmento do genoma de rna -2 de um vírus bipartido, métodos para expressar um a proteína de interesse em um organismo hospedeiro, para melhorar a tradução de uma proteína de interesse heteróloga de um gene ou quadro de leitura aberto, para expressar uma proteína em uma planta e para gerar um proteína de interesse, e, organismo hospedeiro
NZ630869A (en) Compositions and methods for dengue virus chimeric constructs in vaccines
EA201201025A1 (ru) Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них
BR112013022397A2 (pt) vacinas combinadas com doses menores de antígeno e/ou adjuvante
MX2012000036A (es) Vacuna.
BR112014018884A2 (pt) antígenos amplamente reativos computacionalmente otimizados para viroses de influenza h3n2, h2n2, e b
EP1917033A4 (en) VIRUS LIKE PARTICLES AS PARAMYXOVIRUS VACCINES
MX394097B (es) Producción de partículas similares a virus en plantas.
BR112014007474A2 (pt) aumento de rendimento de partícula tipo vírus em plantas
HK1208355A1 (en) Universal influenza vaccine based on heterologous multiple m2e proteins
MX2011007692A (es) Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion.
WO2012047679A3 (en) Consensus antigen constructs and vaccines made there form, and methods of using same to treat malaria
BR112014017242A2 (pt) vlps contendo hpv l2 imunogênico e composições e métodos relacionados
BRPI0816134A2 (pt) Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença.
BR112014011345A2 (pt) partículas tipo vírus da influenza (vlps) compreendendo nicotiana tabacum produzida por hemaglutinina
BR112015023738A2 (pt) vacinas de nucleoproteina influenza

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: MEDICAGO INC. (CA)

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 870240081530 DE 24/09/2024, E NECESSARIO APRESENTAR UMA GUIA DE RECOLHIMENTO, CODIGO 248, RELATIVA A ALTERACAO DE ENDERECO DA CEDENTE. ALEM DISSO, E PRECISO APRESENTAR A GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25G Requested change of headquarter approved

Owner name: MEDICAGO INC. (CA)

B25A Requested transfer of rights approved

Owner name: ARAMIS BIOTECHNOLOGIES INC. (CA)